We also provide the first in vivo data using an orthotopic model to support the notion that targeting eEF-2K may be a useful strategy as a co-therapy for breast cancer to enhance efficacy of commonly used chemotherapeutic agents, such as doxorubicin. Here, EEF2K is linked to breast carcinoma.